NCCN Updates Kidney Cancer Guidelines to Incorporate FDA Approval of Everolimus

Publication
Article
OncologyONCOLOGY Vol 23 No 6
Volume 23
Issue 6

The National Comprehensive Cancer Network (NCCN) has added everolimus (Afinitor) to the NCCN Guidelines for Kidney Cancer as a category 1 option for patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors such as sunitinib (Sutent) and sorafenib (Nexavar). This recommendation comes on the heels of the recent US Food and Drug Administration (FDA) approval of everolimus.

The National Comprehensive Cancer Network (NCCN) has added everolimus (Afinitor) to the NCCN Guidelines for Kidney Cancer as a category 1 option for patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors such as sunitinib (Sutent) and sorafenib (Nexavar). This recommendation comes on the heels of the recent US Food and Drug Administration (FDA) approval of everolimus.

The FDA approval is based on results of a clinical trial showing that the everolimus treatment improved median progression-free survival to 4.9 months compared to 1.9 months in patients who did not receive the treatment.

Recent Videos
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content